Logo image of AKTX

AKARI THERAPEUTICS PLC-ADR (AKTX) Stock Fundamental Analysis

NASDAQ:AKTX - Nasdaq - US00972G2075 - ADR - Currency: USD

0.97  -0.08 (-8.06%)

After market: 0.9799 +0.01 (+1.02%)

Fundamental Rating

0

Overall AKTX gets a fundamental rating of 0 out of 10. We evaluated AKTX against 572 industry peers in the Biotechnology industry. AKTX has a bad profitability rating. Also its financial health evaluation is rather negative. AKTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AKTX had negative earnings in the past year.
AKTX had negative earnings in each of the past 5 years.
AKTX had a negative operating cash flow in each of the past 5 years.
AKTX Yearly Net Income VS EBIT VS OCF VS FCFAKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

AKTX's Return On Assets of -951.98% is on the low side compared to the rest of the industry. AKTX is outperformed by 99.11% of its industry peers.
Industry RankSector Rank
ROA -951.98%
ROE N/A
ROIC N/A
ROA(3y)-169.23%
ROA(5y)-176.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKTX Yearly ROA, ROE, ROICAKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50K -100K -150K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AKTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKTX Yearly Profit, Operating, Gross MarginsAKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, AKTX has more shares outstanding
Compared to 5 years ago, AKTX has more shares outstanding
AKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AKTX Yearly Shares OutstandingAKTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
AKTX Yearly Total Debt VS Total AssetsAKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -135.71, we must say that AKTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -135.71, AKTX is not doing good in the industry: 98.22% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -135.71
ROIC/WACCN/A
WACCN/A
AKTX Yearly LT Debt VS Equity VS FCFAKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.29 indicates that AKTX may have some problems paying its short term obligations.
With a Current ratio value of 0.29, AKTX is not doing good in the industry: 95.74% of the companies in the same industry are doing better.
A Quick Ratio of 0.29 indicates that AKTX may have some problems paying its short term obligations.
AKTX has a worse Quick ratio (0.29) than 95.03% of its industry peers.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
AKTX Yearly Current Assets VS Current LiabilitesAKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AKTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.88% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15%
EPS Next 2Y4.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKTX Yearly Revenue VS EstimatesAKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
AKTX Yearly EPS VS EstimatesAKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKTX Price Earnings VS Forward Price EarningsAKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKTX Per share dataAKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.88%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKARI THERAPEUTICS PLC-ADR

NASDAQ:AKTX (2/21/2025, 8:00:46 PM)

After market: 0.9799 +0.01 (+1.02%)

0.97

-0.08 (-8.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-30 2024-09-30/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners1.36%
Inst Owner Change-99.97%
Ins Owners22.36%
Ins Owner Change3.42%
Market Cap25.68M
Analysts82.86
Price TargetN/A
Short Float %61.68%
Short Ratio2.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-3.67
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.25
TBVpS-0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -951.98%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-169.23%
ROA(5y)-176.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z -135.71
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y15%
EPS Next 2Y4.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.57%
OCF growth 3YN/A
OCF growth 5YN/A